Skip to main content

Table 1 A summary of therapeutic efficacy and adverse events

From: IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer

 

A vs. B

IMpower133

CASPIAN

Efficacy

 PFS (in months)

5.2 vs. 4.3

5.1 vs. 5.4

  HR (95% CI)

0.77 (0.62–0.96)

0.78 (0.65–0.94)

  PFS%

   At 6 months

30.9% vs. 22.4%

45% vs. 46%

   At 12 months

12.6% vs. 5.4%

18% vs. 5%

  OS (in months)

12.3 vs. 10.3

13.0 vs. 10.3

   HR (95% CI)

0.76 (0.60–0.95)

0.73 (0.59–0.91)

   OS% at 12 months

51.7% vs. 38.2%

54% vs. 40%

trAEs

 All grades

94.9% vs. 92.3%

89% vs. 90%

 Grades 3–4

56.6% vs. 56.1%

46% vs. 52%

 SAEs

22.7% vs. 18.9%

13% vs. 19%

irAEs

 All grades

39.9% vs. 24.5%

20% vs. 3%

 Grades 3–4

9.1%* vs. 2.6%*

5% vs. < 1%

  1. A chemotherapy + immunotherapy, B chemotherapy alone, HR hazard ratio, 95% CI 95% confidence interval, trAEs treatment-related adverse events, AEs adverse events, SAEs severe adverse events, irAEs immune-related adverse events
  2. *Calculated using Table S10 in the supplementary appendix provided by the authors